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Most patients who present with cancer have advanced disease and often suffer moderate
to severe pain. Opioid therapy can be safe and effective for use in cancer patients
with pain, but there are rightful concerns about inappropriate opioid use even in the
cancer population. Since cancer patients live longer than ever before in history (and
survivors may have long exposure times to opioid therapy), opioid misuse among cancer
patients is an important topic worthy of deeper investigation. Cancer patients with pain
must be evaluated for risk factors for potential opioid misuse and aberrant drug-taking
behaviors assessed. A variety of validated screening tools should be used. Of particular
importance is the fact that pain in cancer patients changes frequently, whether it is related
to their underlying disease (progression or remission), pain related to treatment (such as
painful chemotherapy-induced peripheral neuropathy), and concomitant pain unrelated
to cancer (such as osteoarthritis, headache, or back pain). Fortunately, clinicians can
use universal precautions to help reduce the risk of opioid misuse while still assuring
that cancer patients get the pain therapy they need. Another important new “tool” in this
regard is the emergence of abuse-deterrent opioid formulations.
Keywords: cancer pain, malignant pain, opioid analgesia, opioids, undertreatment of cancer pain, assessment of
cancer pain
INTRODUCTION
The Cali Cancer Registry (CCR) is the best-known population-based source for descriptive
epidemiology of cancer in Colombia specifically and in South America at large; dating back
to 1962, it is the oldest cancer registry in Latin America (1989). The main drawback to the
CCR is that it offers data for the urbanized area of Cali, but does not provide a full picture
of the large and diverse Colombian nation. A recent study of Colombian cancer incidence
reported that the annual total numbers of all cases of cancer in Colombia (except for skin
cancer) was 17,819 and 18,772 for men and women, respectively (Pineros et al., 2006). The
most frequent cancers in Colombian men were prostate (45.8 per 100,000), stomach (36.0 per
100,000), and lung (20.0 per 100,000); for women, the most common cancers were the cervix uteri
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(36.8 per 100,000), breast (30.0 per 100,000), and stomach (20.7
per 100,000; Pineros et al., 2006). Most Colombians who present
with cancer are in an advanced disease state at the time of
diagnosis. This pattern of a high cancer prevalence and advanced
disease at diagnosis is not uncommon in developing nations.
Pain is a common symptom of cancer, typically worsening
with disease progression. Cancer survivors may likewise suffer
from chronic pain syndromes associated with the cancer
treatments, such as chemotherapy-induced neuropathic pain
(Westerling, 2014). More than half of patients with metastatic
or terminal cancer (64%) experience pain, about 59% of patients
undergoing anticancer treatment experience pain, and about a
third (33%) of cancer survivors report pain (Ripamonti et al.,
2012). About 15% of ambulatory cancer patients and 70% of
palliative patients have pain symptoms (Yennurajalingam et al.,
2012). As more and more patients survive cancer for longer
periods of time, pain treatments must evolve to meet these new
needs. Pain in cancer patients can be particularly challenging to
manage; it is often multimechanistic, severe or even very severe,
and variable with disease progression and treatments. Moreoever,
cancer patients often experience pain ofmultiple types atmultiple
locations.
Assessing and managing pain in advanced cancer patients
falls under the broad therapeutic approach of palliative care.
Physicians should identify and assess the pain, the underlying
causes and the ongoing treatments, and individualize pain
therapy for each patient, bearing in mind that the pain may
change as the disease and/or treatment progress (Portenoy,
2011). An important pharmacotherapeutic modality for cancer
pain remains opioid therapy.
OPIOID THERAPY
Due to concerns about opioid misuse and diversion, opioid
therapy may be under-prescribed and cancer pain go under-
treated. For example, based on opioid analgesic consumption,
Colombia is using far less than what might be considered
an adequate level of opioids for analgesia (actual use of 6.78
mEq inmg per capita in 2010 vs. 204.13 mEq “adequate”
use; Duthey and Scholten, 2014). Indeed, opioid consumption
patterns indicate that about two-thirds of the world’s population
(66%) has virtually no access to opioid analgesics and just 7.5% of
the world’s population has adequate consumption levels to meet
its pain burden (Duthey and Scholten, 2014). In general, opioids
are not prescribed as often as they ought to be inmany developing
nations.
There are many reasons for the uneven consumption patterns
of opioid analgesics. Opioids are not widely available in some
regions for legal, social, public health, economic, or cultural
reasons. There is also reluctance to prescribe available opioid
analgesics due to lack of physician training, concerns about
addiction, regulatory restrictions, potential legal liabilities, and
patient attitudes. The reticence to make use of available opioid
analgesics has been termed “opiophobia”(Rhodin, 2006).
The appropriate care of cancer patients requires pain control;
indeed, pain management has been stated to be a fundamental
human right (Daher, 2010). In 1988, the World Health
Organization (WHO) advocated the use of oral morphine for the
management of moderate to severe cancer pain (World Health
Organization, 1988). Balancing concerns about opioid misuse
against the need for appropriate pain control has resulted in
what has been called “opioid risk management.” This approach
recognizes the inherent risks in opioid therapy, but weighs them
against the needs of patients dealing with moderate to severe or
very severe cancer pain. The goal of opioid risk management
is to minimize the harms associated with opioid therapy while
maintaining access to opioid therapy for the control of pain.
INAPPROPRIATE USE, MISUSE, AND
ABUSE OF OPIOIDS
It has been estimated that over 10% of chronic pain patients
misuse opioid analgesics, i.e., that they take the drugs
inappropriately. Opioid misuse encompasses taking the drugs
in any way not prescribed, whether intentional or inadvertent
and whether or not harm results (Garland et al., 2013).
Inappropriate use of opioids may include misuse (e.g., taking
more drug than prescribed for a “bad day”), abuse (taking the
drugs recreationally), diversion (selling the drugs rather than
consuming them), and addiction. The fact is that most cancer
patients who are prescribed opioid analgesics appropriately will
not misuse them. However, some will misuse opioids and the
identification of patients at risk for opioid misuse remains a
challenge. This problem is exacerbated by the fact that risk factors
change with time and situation (Pergolizzi et al., 2012).
The risk of opioid abuse specifically in cancer patients is a
subject of ongoing study. As cancer treatment improves, patients
live longer, many in chronic pain. Their exposure to opioids
will increase and the risks of misuse may be expected to rise
(Starr et al., 2010). It had long been accepted among clinicians
that cancer patients were at relatively low risk for opioid misuse
(Porter and Jick, 1980). There were many sound reasons for this
thinking. Decades ago, cancer mortality was much higher and
thus patients used opioids only for a short period of palliative
care. The idea of a cancer patient surviving for years—and
taking opioid pain relievers for years—is more common today.
Although cancer patients are typically older (Starr et al., 2010),
and older age mitigates the risk for inappropriate opioid use,
adequately defining and describing opioid misuse, abuse, and
addiction can be very difficult in a medically ill population (Starr
et al., 2010).
RISK FACTORS FOR OPIOID ABUSE IN
CANCER PATIENTS
Cancer patients typically have a heavy symptom burden and a
high degree of disease-related stress. Cancer can put enormous
strain on the patient and caregivers, incorporating anxiety about
everything from morbidity and mortality to financial worries
and fears about how the disease will impact the family structure.
These factors can force patients to rely on coping mechanisms
over the course of their illness, which may last many months or
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years. “Chemical coping” is a term used to describe a continuum
of inappropriate opioid behaviors to help manage stress or other
similar symptoms; chemical coping may range from mild forms
of misuse with no harmful consequences to outright addictive
behaviors (Del Fabbro, 2014). Although there are no studies
about chemical coping in cancer patients of which the authors
are aware, this would seem to be a particularly important area for
future investigation.
In general, risk factors for inappropriate use of opioids appear
to be the same for cancer and noncancer pain patients. These
include a history of substance abuse, active substance abuse
(including but not limited to alcoholism and/or illicit drug use),
tobacco use, mental health disorders (such as depression and
anxiety disorders), and psychological traumas (such as childhood
abuse; Passik and Kirsh, 2004; Compton and Volkow, 2006;
Sullivan et al., 2006; Hojsted and Sjogren, 2007; Jamison et al.,
2011; Pergolizzi et al., 2012). Cancer patients are not immune to
these risk factors. In fact, they may have higher rates of some of
the risk factors (such as smoking) than the general population.
Alcoholism is also thought to be more prevalent among cancer
patients, although it is not always diagnosed (Bruera et al., 1995;
Martin et al., 2002; Del Fabbro, 2014).
The conundrumwith cancer patients is that even patients with
clear risk factors for opioid misuse (such as an active addiction)
may legitimately have moderate to severe pain associated with
their malignancy. For terminally ill patients with severe pain,
addictive disorders were once considered non-issues; the patient
near death was given medications to stop the pain without
concern about potential addiction. With patients surviving
cancer for longer and longer periods of time, these issues are
no longer minor. Moreover, unchecked substance abuse may
exacerbate suffering in the palliative patient, complicate the
management of other cancer-related symptoms, and have a
distressing effect on the patient’s family (Passik and Theobald,
2000). Thus, oncologists today may need to consult with pain
specialists and experts in addiction to help manage pain in cancer
patients at high risk for opioid misuse.
The four A’s of pain management outcomes are: analgesia,
activities of daily living, adverse events, and aberrant drug-taking
behaviors (Passik and Weinreb, 2000). Physicians must assess
pain, screen for risk, and then consider treatment options,
including nonopioid treatments and nonpharmacological
treatments. Owing to the nature of disease progression and
cancer therapy, pain assessments must be performed regularly to
adequately capture changing pain symptoms. Gourlay described
universal precautions for prescribing opioid analgesics, including
assessment of risk, informed consent, treatment agreements
(spelling out in writing the expectations of the physician
and clinic), and regular re-assessments of both pain and
aberrant-drug taking behaviors (Gourlay et al., 2005).
Pain intensity must be evaluated frequently in cancer patients.
Cancer patients often have multiple pain sites and each site
should be assessed individually, noting that not all pain in
cancer patients is necessarily related to the cancer. They may
have osteoarthritis pain, for example. The duration of pain,
intensity, and aggravating and/or mitigating factors should be
noted. The patient should be encouraged to describe the pain at
each site, prompted if necessary by the clinical team with such
words as burning, dull, throbbing, electrical, “pins and needles,”
stabbing, and so on. A full medical history should be obtained,
including the other drugs as well as over-the-counter products or
supplements the patient is taking.
To assess for the potential of opioid misuse, the physician
must review specific topics with the patient known to be risk
factors for opioid misuse and abuse (see Table 1). Of course,
certain patients may not be forthcoming about their use of drugs
and alcohol. In one survey, 27% of potential patients concealed
their use of illicit drugs from a physician evaluating them for
pain therapy (Manchikanti et al., 2004). Clinicians should be
thorough, careful, and respectful to patients in going over these
points, but be wary that many patients will be less than truthful
(Gourlay et al., 2005).
Documentation is a crucial part of pain therapy for any
patient, including diagnostic results, pain assessment evaluations,
patient history, risk assessments, treatment objectives, and
discussions between the clinical team and patient about the risks
and benefits of opioid therapy. Over the course of treatment,
changes in the patient’s condition, therapy, and evaluations
should be assessed and carefully documented.
Aberrant drug behaviors are exhibited by patients prescribed
opioids include (but are not limited to) demands for stronger
or more analgesics, “lost” prescriptions (especially if this
occurs frequently), demands to see the physician without
an appointment, and insisting on specific pain relievers by
product name and dosage (Passik and Kirsh, 2004). Aberrant
drug-related behaviors can be deceptive. In other words,
while these behaviors can be highly suggestive of misuse,
some patients will honestly lose prescriptions or show up at
the clinic without an appointment. Furthermore, in cancer
patients, it is important to differentiate between addiction and
pseudoaddiction, both of which may provoke aberrant drug-
related behaviors. Pseudoaddiction occurs when the patient has
inadequate analgesia and seeks greater pain relief; addiction
occurs when the patient uses the drug compulsively, may have
strong drug cravings, and has little control over drug use even
when understanding that the drug is harmful (Katz et al.,
2007). Both addiction and pseudoaddiction will result in patients
complaining, sometimes quite assertively, that they need more
and stronger pain relievers. Patients who are addicted to opioid
pain relievers should be tapered off them; patients who are
“pseudoaddicted” should be titrated and may actually need larger
doses or different opioid analgesics.
Some of the outward signs suggestive of opioid misuse or
abuse appear in Table 2. Note that these signs may occur in
patients taking opioids as prescribed or may be attributable
to other factors. Cancer patients, in particular, may exhibit
signs related to their underlying disease or adverse effects of
aggressive anticancer treatments that can mimic signs of abuse.
Furthermore, cancer is a highly stressful condition thatmay cause
patients to appear anxious, fearful, and agitated.
So-called aberrant drug-taking behaviors can also be
suggestive of opioid abuse (Passik and Kirsh, 2004). These
include patients with erratic habits (failing to show up for an
appointment or coming to the clinic without an appointment),
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TABLE 1 | A short overview of risk factors for opioid inappropriate use (Pergolizzi et al., 2012).
Factor Considerations Comments
Alcohol use Present use, inappropriate use, and alcoholism are risk
factors as is recent history of alcohol abuse (Ives et al., 2006).
CAGE assessment is a simple and useful tool (Parsons et al., 2008).
Cocaine use Present or recent history of this drug is a strong predictor of
opioid inappropriate use (Ives et al., 2006).
A history of substance abuse more than five years in the past is not
associated with opioid inappropriate use (Passik et al., 2011).
Substance abuse (other) Includes marijuana, stimulants, legal, and illicit drugs (Ives
et al., 2006).
Benzodiazepines in particular are associated with opioid
inappropriate use (Skurtveit et al., 2010). Thus, among patients with
a history of drug abuse, risk can be stratified by type of drug
(cocaine and benzodiazepines are higher risk than marijuana, for
example).
Family history of substance
abuse
May be a risk factor even if the patient does not abuse
substances himself (Prasant et al., 2006).
Applies to first-degree relatives only.
Current prescription for
opioids
Long-term use of opioids is a risk factor for inappropriate use
(Edlund et al., 2007).
Mental health and mood
disorders
Includes dissociative disorders, bipolar disorders, depression,
schizophrenia, post-traumatic stress disorders, and others
(Pergolizzi et al., 2012).
Mental health disorders are prevalent among those with chronic pain
syndromes (Manchikanti et al., 2002).
Gambling addiction Gambling addiction has been associated as a risk for opioid
inappropriate use (Petry et al., 2005).
Legal problems In particular, history of drunk driving, drug convictions, or
motor vehicle collisions (Turk et al., 2008).
Trauma Being a victim of a crime or abuse (Khoury et al., 2010;
Vaughn et al., 2010).
Sexual abuse in childhood is a risk for both sexes but the risk is
higher for women (Kendler et al., 2000).
Young age Younger individuals are at greater risk for opioid inappropriate
use than older people (Manchikanti et al., 2006).
Age at first exposure to opioids may be a risk factor (risk is greater
for younger exposure; Becker et al., 2008) and should be
considered in addition to the patient’s current age.
TABLE 2 | Signs that may suggest opioid inappropriate use and alternate
explanations in cancer patients (Gourlay et al., 2005).
Sign Alternate explanation(s)
Unkempt appearance Patient may be depressed or overwhelmed by illness;
patient may have symptoms related to cancer
treatments that cause them to feel sick all of the time
and thus neglect their appearance
Anxiety, nervousness,
agitation
Patient may be upset about cancer, his or her prognosis,
or have fears relating to treatment, home or hospital
care, or financial worries
Sniffles Allergies, cold, sinus problems, symptoms associated
with cancer treatments
Watery eyes Allergies, cold; symptoms associated with stress or fear
Cough Cancer-related cough; allergies, cold, heart burn
Lethargy Fatigue, depression, disease progression, lethargy
related to treatments, especially chemotherapy, lethargy
associated with other drugs the patient might be taking
Drowsiness, nodding
off
Fatigue, disease progression, adverse effect related to
treatment especially chemotherapy or other drug therapy
Skin lesions (from
injecting drug)
Possibly related to other drug therapies associated with
the cancer; skin disorders, rash
requesting appointments at the end of the day when they
anticipate clinicians will be in a hurry, reluctance or refusal
to undergo physical examination, failing to keep referral
appointments, refusing to divulge past medical history, or
unusual behaviors such as obvious agitation and emotional
outbursts. Physicians should train the entire clinical team to be
alert to such aberrant behaviors, but their “diagnostic power” is
limited. While such behaviors suggest potential opioid misuse,
they do not prove it. Not every cancer patient who is in a hurry
or who has poor social skills is a drug abuser.
SCREENING TOOLS
Several assessment instruments have been developed to help
clinicians better identify patients at risk of opioid misuse. These
tools were not all developed specifically for cancer patients, but
they can be used in this population.
CAGE and CAGE-AID
The original CAGE survey dating back to 1974 has four questions
related to alcohol use (Mayfield et al., 1974). It was adapted to
include drugs (AID) in the composite CAGE-AID instrument.
Participants are asked to respond yes or no to four questions
that give the survey its acronym: (1) are they trying to use less
(“cutting down”), (2) are they annoyed that people criticize their
substance use (“annoyance”), (3) do they feel guilty about their
substance use (“guilty”), and (4) do they need to use the substance
first thing in the morning to get going (“eye-opener”). The test
can be used for alcohol alone, as originally intended, or for
other substances (CAGE-AID). The rule of thumb is that one yes
warrants further evaluation of the patient, and two or more yes
answers strongly suggests substance abuse. The CAGE survey is
easy to use and is familiar to most clinicians, but it may be of
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limited utility and accuracy in patients with psychiatric disorders
(O’Connell et al., 2004).
Addiction Behaviors Checklist
The Addiction Behaviors Checklist (ABC) was designed to
evaluate patients prescribed opioid analgesics to manage
persistent pain (Wu et al., 2006). The checklist is filled out by
the clinician, who evaluates the patient at the current office visit
and also notes relevant behavioral changes since the last visit. It
is a succinct, targeted survey that takes about 10min to complete.
A score of 3 or more on the 20-question checklist suggests that
opioids are being used inappropriately. A study of 136 chronic
pain patients found it to be a viable assessment tool (Wu et al.,
2006).
Opioid Risk Tool
The Opioid Risk Tool (ORT) evaluates 10 psychosocial risk
factors for opioid abuse, including history of substance abuse,
sexual abuse, and mental health disorders. ORT scores classify
patients as being at low, moderate, or high risk for opioid misuse.
Notably, ORT was specifically designed and validated for use in
cancer patients (Barclay et al., 2014).
Screener and Opioid Assessment for
Patients with Pain—Short Form
The Screener and Opioid Assessment for Patients with Pain—
Short Form (SOAPP-SF), a subset the longer form of the original
SOAPP 14-item questionnaire, is a 5-item questionnaire to be
filled out by the patient. Patients who score 4 or more are
considered to be at high risk for opioid abuse. SOAPP-SF has a
sensitivity of 0.86 and specificity of 0.67 with a 33% chance of a
false positive (Koyyalagunta et al., 2013).
Pain Assessment and Documentation Tool
The Pain Assessment and Documentation Tool (PADT) is a
short survey completed by the patient which evaluates analgesia,
activities of daily living, and adverse events. A checklist on the
form is to be completed by the physician evaluating the patient’s
potential aberrant drug-related behaviors (including mood
changes, reports of stolen prescriptions, arrests, medication
hoarding, and so on).
UNDERSTANDING RISKS INHERENT IN
THE CANCER POPULATION
Ongoing or a recent history of substance abuse and certain
mental health disorders are known risk factors for opioid misuse
and abuse, but the specific prevalence of these conditions in
the cancer population has not been thoroughly elucidated.
Indeed, the cancer population has changed considerably in
recent decades with more and more patients undergoing longer
treatments and surviving longer with the disease, in remission,
or cured. It has been estimated that about 20% to 50% of
cancer patients have some psychiatric disorder, most frequently
depression (Grassi et al., 1996, 2005; Pirl, 2004). Mental health
disorders in cancer patients may relate to the patient’s emotional
response to a devastating diagnosis or it may be associated with
the patient’s general physical condition, possibly due to metabolic
changes. About 10% to 30% of cancer patients are reported to
have anxiety disorders (Mehnert et al., 2007; Brown et al., 2009),
which often relates to their diagnosis and uncertainty about the
future.
The use and abuse of alcohol has been associated with certain
cancers, in particular, breast, colon, rectal, esophageal, larynx,
liver, mouth, and pharynx cancer (Montoya, 2013). A study from
Brazil found alcohol abuse rates of 17.2% and tobacco abuse rates
of 27.3% for cancer patients (Polidoro Lima and Osorio, 2014).
The rate can be much higher for specific cancers. For instance,
epidemiological studies found that 70% of mouth cancer patients
were heavy drinkers. Alcohol drinkers are more likely to smoke
(Jegu et al., 2013) and smoking has well-known associations
with cancer. Thus, certain cancer patients may have higher rates
of certain risk factors for opioid abuse than do the general
population.
Another concern in stratifying risk for opioid abuse in cancer
patients is terminology related to longer-living cancer patients
(Bell and Ristovski-Slijepcevic, 2013). For example, clinicians
may use the term “cancer survivors” to describe either: those in
treatment; those in periods of remission but expected to succumb
to the disease; and those who may be cured (Harrop et al., 2011).
Yet each category of survivor has different needs and burdens,
including different risk levels for opioid misuse. Furthermore,
many “cancer survivors” have chronic pain syndromes, that
necessitate long-term opioid therapy. New definitions and
methodologies must be developed to better evaluate risk factors
for opioid abuse in diverse populations—for example, newly
diagnosed cancer patients vs. patients currently in remission but
dealing with chronic pain or treatment-related pain syndromes.
Indeed, the subject of chronic pain in cancer survivors will be of
increasing importance for pain specialists, as this population of
patients is likely to increase in number and to have special needs
with respect to long-term analgesia.
CLINICAL MONITORING
Urine Drug Testing
Cancer patients on opioid therapy require regular clinical
monitoring and assessment to maximize appropriate treatment
and minimize misuse. Urine drug testing (UDT) is a simple,
inexpensive, and familiar way to screen patients for inappropriate
drug use (Pergolizzi et al., 2010). Clinicians must be aware of
the specificity and sensitivity of the test methods; some tests, for
example, may not detect synthetic opioids (Heit and Gourlay,
2004). Not all commercial UDT facilities screen for all substances;
this must be discussed in advance with the laboratory. UDT
for cancer patients prescribed an opioid is conducted in order
to evaluate the metabolism of opioids (unlike other UDT, the
presence of opioids in the urine in this case is appropriate)
and the absence of illicit drugs. UDT should be discussed in
advance with the patient. It may be done randomly, at clinician
request, or on a set schedule. In addition to providing insight into
the patient’s use of opioids, it provides objective documentation
of the patient’s compliance with the treatment plan and can
serve as an important conversation point with the patient.
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Physicians should resist the urge to draw definitive conclusions
from one unexpected UDT result, but rather should use this as
an opportunity to discuss drug therapy with the patient. False
positives and false negatives are not uncommon.
In some instances, UDT results will not detect the prescribed
opioid medication. There may be several reasons for this,
including: the patient may be misusing their medications, either
by binging (and thus not having any more left); the patient may
be diverting the drugs and selling them rather than taking them;
or, the patient may be noncompliant and not taking the drugs on
“good days.” Any of these situationsmust be addressed. However,
unexpected UDT results can also occur due to laboratory errors
or screens that are not sensitive enough to detect the particular
opioid in question. Unexpected or suspicious UDT results should
be viewed first-and-foremost as an opportunity to discuss opioid-
taking behaviors with the patient.
Treatment Agreements
A treatment agreement is a written document that spells out in
plain language the goals, risks, and benefits of opioid therapy
for a given patient. These agreements may be of great or limited
utility, depending on how they are presented and administered
(Anderson and Burris, 2010; Starrels et al., 2010). The main
purpose of a treatment agreement is to make sure that the patient
is fully aware of the risks as well as the benefits of opioid therapy
and to specify how treatment will be conducted. It also serves as
excellent documentation for the clinic that these matters were
discussed frankly and clearly with the patient. For example,
the treatment agreement should mention that UDT will be
conducted and under what conditions (such as random UDT is
part of therapy). It may also specify that patients can be subjected
to periodic pill counts. The treatment agreement should also state
what constitutes inappropriate opioid use and that there may be
consequences to opioid misuse. The treatment agreement should
also explain the risks of opioid therapy, including the potential
side effects.
Assessments
Cancer can be a progressive disease and involve aggressive
treatment modalities. Therefore, pain in cancer patients may
change in intensity, nature, and location. Periodic pain
assessments are important for all pain patients, but none
more than cancer patients. Patients should be encouraged not
only to provide numeric or other quantitative ratings of pain
intensity, they should also be asked about qualitative pain
descriptions. Other symptoms and details about treatments
should be considered when evaluating the patient’s pain. For
example, chemotherapy may induce painful neuropathy that
may resolve in whole or in part when chemotherapy concludes
(LeQuang and Pergolizzi, 2012).
ABUSE-DETERRENT FORMULATIONS
Abuse-deterrent formulations (ADFs) of specific opioid
analgesic products are commercially available or in development.
These formulations are specifically designed using innovative
technologies to resist or deter abuse (Raffa et al., 2012). The
goal of an ADF is to make it difficult for a potential abuser to
extract the opioid and inject, inhale, or take rectally. ADFs do
not prevent oral opioids from being consumed as oral agents.
The main types of ADF strategies on the market are tablets that
resist crushing, resist dissolving (or turn into a viscous glue),
or incorporate an aversive agent such as niacin, or an opioid
antagonist (such as naloxone). In theory, an ADF could be
created as a prodrug, but no such products are commercially
available in development to the best of the authors’ knowledge.
In addition to ADFs, abuse-deterrent packaging is
being developed, including packaging with radiofrequency
identification (RFID). The RFID is a tiny device (chip) which
contains essential data in the form of an electronic product code
and a serial number unique to each product. RFID technology
allows opioids to be tracked throughout the supply chain.
While large-scale longitudinal studies may be required to
demonstrate the effectiveness of such ADF products in reducing
opioid abuse, when ADF OxyContin was released, the average
diversion rate decreased 60% (RADARS System, 2011). Other
opioids decreased in diversion when an ADF formulation was
introduced to market, but not by such a marked amount. This
suggests that ADFs reduce the abuse of that particular product,
but possibly not overall opioid abuse. Abusers may simply
migrate to a different product.
DISCUSSION
Not so long ago, a cancer diagnosis usually relegated the patient
to palliative care and opioid therapy was viewed as a kindness,
with no need for concern about long-term abuse. Today, cancer
patients live longer, have extended exposures to opioids, and
exhibit at least the same if not greater risk factors for opioid
misuse than patients struggling with chronic but nonmalignant
pain. A lot has changed since 1988 when the WHO advocated
almost the routine use of oral morphine for cancer patients
dealing with moderate to severe pain with no particular warnings
about long-term exposure (World Health Organization, 1988).
Today, clinicians must be mindful that many patients “survive”
cancer and live for many years, but sometimes with chronic pain
as a consequence of the disease or its treatment.
Cancer pain is prevalent, often severe to very severe, and can
markedly diminish the patient’s function, quality of life, and even
mental health. Pain specialists must provide effective and safe
analgesic relief to those dealing with cancer pain, but, it is no
longer realistic to dismiss concerns about addiction because the
patient has cancer. Indeed, cancer patients may be at special risk
for opioid misuse, abuse, and even addiction.
Much has been learned about stratifying risk factors for opioid
abuse and managing this risk. Fortunately, most cancer patients
will not use opioid analgesics inappropriately, although many
will need opioid pain relievers at least for a time period in
the trajectory of their illness. Most cancer patients who are
prescribed opioid analgesics will derive safe and effective pain
relief from these products. Thus, it is neither scientifically sound
nor medically compassionate to remove opioid analgesics from
the cancer patients who may need them. On the other hand, it is
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important to recognize that inappropriate opioid use, abuse, and
addiction, are possible among cancer patients and steps must be
taken to safeguard them. A subset of cancer patients may even be
at elevated risk for opioid abuse.
As with much in pain medicine, the care of cancer patients
with pain can be summarized in a few practical steps. First,
cancer patients with pain must be treated systematically. It is
less important what the system is than the fact that a system
is in place. This system should include patient interview and a
thorough medical history, pain assessments, evaluations, patient
education, informed consent, and treatment agreements. These
are crucial to success and should not be undertaken haphazardly
or casually.
Second, clinicians should educate patients about the risks
and benefits of any analgesic therapy and listen carefully to
the patient’s own goals. Some patients will resist taking opioid
analgesics for any number of reasons. Informed consent and
a patient agreement offer excellent documentation as well as
set forth terms and conditions in unequivocal language. The
physician should consider the patient’s risk factors for opioid
misuse. These risk factors sometimes create a conundrum in
that a patient may have a legitimate pain condition necessitating
opioid therapy, but clear risk factors for misuse, such as active
substance abuse (Savage et al., 2008). Such situations do not
necessarily preclude the use of opioid analgesics, but do require
close supervision.
Third, it is important to recognize that pain control
may rely on multiple simultaneous strategies, including
nonpharmacological methods. In some cases, pain may be
managed with nonopioids, multimodal nonopioid therapy, a
combination of nonopioid, and nonpharmacological methods,
or fixed-dose combination products that reduce the amount of
opioid use. The use of multiple pain strategies requires careful
patient education, but can be very effective, particularly in
willing, compliant patients.
Fourth, clinicians should monitor patients closely and discuss
the monitoring tools (e.g., pain intensity assessments, UDT,
pill counts) in advance. Pain levels must be assessed often.
Patients taking opioids should be informed about potential
side effects and these effects should be managed proactively.
Since opioid-associated side effects can be treatment limiting,
it is crucial to long-term therapeutic goals to manage them
effectively.
Fifth, clinicians must be vigilant about abuse, even in patients
who did not seem to be at risk when opioid therapy commenced.
Risk factors change over time (Pergolizzi et al., 2012). When it
is suspected or known that a patient is misusing opioids, the
physician should be willing to firmly but respectfully refer the
patient to a psychologist or addiction specialist. Patients should
not be made to feel that they are jeopardizing analgesia by being
forthcoming about issues of misuse or addiction, but these issues
must be addressed.
CONCLUSION
Finally, pain specialists treating pain in cancer patients should
be conscientious in documenting their findings, evaluations, and
other aspects of care. Cancer patients can be long-term patients
with constantly changing needs and this requires diligence in
documentation. Best practices should be conscientiously applied
to mitigate the potential for abuse, but the clinician and all
stakeholders must be aware that as long as opioids are used, there
is a degree of risk.
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